Technical
Channels

Drug Discovery

Drug Development

Drug Manufacturing

Drug Delivery

Clinical Trials

Regulatory and Legal

Alliances and Mergers

QA/QC and Compliance

Pharmaceutical Processing and Packaging

Change text size [+] [-]

Pall presents five-year business plan

Tuesday, November 18, 2008
 Email This |  Printer Friendly

Pall Corp hosted an investor conference at the Grand Hyatt Hotel in New York City late last month.

The company presented its five-year strategic business plan for fiscal 2009 - 2013 to a group of financial analysts.

The presentation was also webcast live to a broader audience.

By the end of Pall's new five-year plan, sales CAGR is targeted to increase to between 7% and 9% with earnings per share ranging from $4.25 to $5.60, excluding restructuring and other charges and the impact of currency translation.

It has also updated guidance for fiscal 2009.

Sales are projected to grow between 4% and 6.5% with earnings per share of $2.10 to $2.30, excluding restructuring and other charges and the impact of currency translation.

The new plan calls for the establishment of a Swiss entity as part of the company's initiatives to rationalize its European infrastructure.

The new company, located in the canton of Fribourg, will lead and support sales, manufacturing, supply chain and other European functions.

The company also provided a target tax rate of 25-27% by fiscal 2013.


Share this:   Del.icio.us | 
Ask the Expert

What technologies and/or practices can Asian pharma manufacturers adopt today, to ensure quality in their products?

Digital Edition



Singapore's Preclinical R&D industry should differentiate itself in Asia by competing on quality rather than on price.
Yes
No
View results


ABOUT PHARMA ASIA | FREE SUBSCRIPTION | CONTACT US

© 2010 Ten Alps Communications Asia. All rights reserved.
Use of this Web site is subjected to its Terms and Conditions of Use. View our Privacy Policy